Pfizer Inc
SGO:PFE
Pfizer Inc
SGO:PFE
Price:
49.19
USD
-0.36%
Market Cap:
$165.2B
Add Note
Add Target
Capture your thoughts and set a target
Decide at what price you'd be comfortable buying and we'll help you stay ready.
Based on
Margin of Safety
0%
10%
20%
30%
40%
50%
Your Price Target
Linked to
current price
· In Buy Zone
Loading
Note attached
Choose the stock you wish to monitor with a price target
Recently Viewed
|
P
|
Pfizer Inc
SGO:PFE
|
US |
|
Rent the Runway Inc
NASDAQ:RENT
|
US |
|
I
|
International Graphite Ltd
ASX:IG6
|
AU |
|
China Yongda Automobiles Services Holdings Ltd
HKEX:3669
|
CN |
|
Bank Sinarmas Tbk PT
IDX:BSIM
|
ID |
|
R
|
Raven Property Group Ltd
LSE:RAV
|
GG |
|
L
|
Lam Dong Pharmaceutical JSC
VN:LDP
|
VN |
|
N
|
New Residential Urban Development Holdings Corp
VN:KDM
|
VN |
|
Bexil Corp
OTC:BXLC
|
US |
|
B
|
B3 SA Brasil Bolsa Balcao
OTC:BOLSY
|
BR |
|
Beenos Inc
TSE:3328
|
JP |
|
Orpea SA
OTC:ORPEF
|
FR |
|
Norcros PLC
LSE:NXR
|
UK |
|
L
|
Left Field Printing Group Ltd
HKEX:1540
|
HK |
|
Triller Group Inc
NASDAQ:ILLR
|
US |
|
Partners Group Holding AG
SIX:PGHN
|
CH |
Multiples-Based Value
The
Multiples-Based Value for
Pfizer Inc (PFE)
under the Base Case is
hidden
USD.
Compared with the current market price of 49.19 USD, the stock appears
hidden
.
Multiples-Based Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.
Relative Valuation FAQ:
PFE Multiples-Based Value
LOCKED
Multiples Across Competitors
PFE Competitors Multiples
Pfizer Inc Competitors
Pfizer Inc Competitors
All Countries
| Market Cap | P/S | P/E | EV/EBITDA | EV/EBIT | ||||
|---|---|---|---|---|---|---|---|---|
| US |
|
Pfizer Inc
SGO:PFE
|
158.2B USD | 2.5 | 20 | 7.7 | 10.2 | |
| US |
|
Eli Lilly and Co
NYSE:LLY
|
875.9B USD | 13.5 | 42.6 | 28.8 | 30.7 | |
| US |
|
Johnson & Johnson
NYSE:JNJ
|
580.2B USD | 6.1 | 21.5 | 15 | 18.4 | |
| CH |
|
Roche Holding AG
SIX:ROG
|
248.4B CHF | 4.1 | 19.7 | 11.6 | 13.1 | |
| UK |
|
AstraZeneca PLC
LSE:AZN
|
232B GBP | 5.2 | 30 | 16.6 | 23.4 | |
| US |
|
Merck & Co Inc
NYSE:MRK
|
299.1B USD | 4.5 | 16.1 | 10 | 12.2 | |
| CH |
|
Novartis AG
SIX:NOVN
|
236.4B CHF | 5.1 | 20.7 | 12.8 | 16.5 | |
| IE |
E
|
Endo International PLC
LSE:0Y5F
|
244.4B USD | 105.4 | -83.6 | 386.8 | 970 | |
| DK |
|
Novo Nordisk A/S
CSE:NOVO B
|
1.1T DKK | 3.4 | 10.2 | 7.6 | 8.9 | |
| US |
|
Bristol-Myers Squibb Co
NYSE:BMY
|
119.4B USD | 2.4 | 16.6 | 7 | 8.7 | |
| UK |
|
GSK plc
XETRA:GS71
|
100.1B EUR | 2.6 | 14.8 | 8.1 | 10 |
P/S Multiple
P/E Multiple
EV/EBITDA Multiple
EV/EBIT Multiple
